Rallybio Q2 net loss $16.2M; cash $88.6M; RLYB212 Phase 2 on track for Q4 2024

Rallybio Corp

2024-Q2 EPS reported -$0.83 revenue$299,000

Q2 net loss $16.2M ($0.37/share) vs $18.6M ($0.46/share) in Q2 2023.
Revenue $0.3M from J&J collaboration; no revenue in prior year.
Cash, equivalents, and securities $88.6M as of June 30, expecting runway into mid-2026.
RLYB212 Phase 2 trial in pregnant women at risk of FNAIT remains on track to start Q4 2024.
Epidemiological analysis estimates >30,000 higher-risk pregnancies/year in North America and major European countries, 40% above prior estimates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.